INSIGHTEC’s Women’s Health treatment option provides a non-invasive solution for symptomatic Uterine Fibroids and Adenomyosis. This non-invasive option spares the uterus, enabling future fertility. Focused ultrasound waves, guided by magnetic resonance imaging are used to safely ablate tumor tissue, ensuring a high rate of effectiveness with minimal side effects. Performed on an outpatient basis, patients can return to work and normal activity within days. Prevalence of uterine fibroids increases with age. In the US, 40% of 35 year old women suffer from uterine fibroids, while almost 70% by the age of 50*. Many patients tend to wait more than 3 years from discovery to treatment**, while in the meantime fibroids are growing. Today’s most common procedure for treating symptomatic, large uterine fibroids is Hysterectomy. This treatment option leaves women with no uterus and no option of having children in the future. Hysterectomy is also known to have some post procedure chronic side effects such as changes in hormonal balance, heart problems and more. That’s why having a uterus preserving treatment option, such as MRgFUS, is so critical.

*Khan AT, Shehmar M, Gupta JK Uterine fibroids: current perspectives Int J Womens Health. 2014; 6: 95–114. doi: 10.2147/IJWH.S51083; Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM: High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003, 188(1):100–107 **, survey of 968 women between 2011 and 2012


How it works

Non-invasive MRgFUS Treatment of Uterine Fibroids and Adenomyosis

    • Uterine Fibroids
      Read More close

Why Insightec Women's Health?

  • Clinical Value

    Safe, incision-less treatment that presents very low rate of adverse events and allows for real-time feedback of fibroid ablation

  • Patient Value

    A low-pain alternative to surgery that’s also uterus preserving and offers quick recovery and return to normal activity within 1-2 days

  • Operational efficiency

    An outpatient procedure that allows for medical facilities to expand their range of services and improve the throughput of their MR room

Physician Testimonials

Dr. Jaron Rabinovici states, “Uterine Fibroids are the most common tumor of the female pelvis, causing women to seek the ultimate treatment for their symptoms. Exablate MRgFUS gives the woman a choice to have a much better, efficacious, treatment for uterine fibroids than surgery".

Dr. Med. Matthias Matzko, of Helios Amper Hospital in Dachau, Germany speaks about the many advantages Exablate MRgFUS has to offer for both radiologists and patients, and the role of image guided procedures play in the future of medicine.

Regulatory Approvals

Per Indication
  • Uterine Fibroids

  • Adenomyosis

Please fill all the following details and we get in touch with you (* Required)

agreement Error

Thank You!

Thank you for contacting us! We will get back to you shortly.

Thank You!

This site is brought to you by INSIGHTEC, © 2017 INSIGHTEC Ltd. All rights reserved

NGSoft logo